QualityDipStocks / Health Care · Medical instruments
Insulet PODD
Outside our quality screen, so we don’t track its dips. It’s 57% below its 52-week high.
Outside our quality screen, trading above our fair value estimate, 8% over its Market Value.
- Fair value est.
- $130.56−13%
- Market Value
- $138.35price +8%
- Off 52-wk high
- −57%
- Risk vs market
- Lowbeta 0.25
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $149.68
- 52-wk lowlowest close, 1 year$130.47−12.8%
- Fair value est.base case$130.56−12.8%
- Market Valueavg paid since Sep 21$138.35−7.6%
- PriceFri Oct 30 close$149.68you are here
- 52-wk highhighest close, 1 year$346.36+131.4%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 15.0% ±2 points. Bear = 10.5% and 13.0%; bull = 8.5% and 17.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, PODD’s free cash flow would need to grow about 18% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much PODD moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 3.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.25
- Volatility
- 45% vs 13% SPY
- Correlation SPY
- 0.07
- Correlation QQQ
- −0.05
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthSales compounded 28% a year from FY2022 to FY2025.
GrowthSales grew 29% to $3.1B over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityOperating margin widened to 17.5% in FY2025 from 13.0% in FY2023 (SEC filings).
Balance sheetPaid down debt: $949M at FY2025, 33% less than at FY2023.
ProfitabilityReturn on equity of 26% over the last 12 months.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $130.56, 13% below the price.
GrowthDiluted EPS fell 40% to $3.48 in FY2025.
ProfitabilityReturn on equity fell 12 points in two fiscal years, to 16% in FY2025.
Cash returnsFree cash flow fell 27% over the last 12 months vs the 12 months before.
ValuationTrades 8.2% above its Market Value of $138.35, the average price paid since the Sep 21 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on Insulet in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical instruments
All fundamentals
P/E 27.7 · FCF yield 2.8% · ROE 26%
Valuation
- P/E
- 27.7×Health Care median 29.2×
- Price / FCF
- 35.4×
- FCF yield
- 2.8%
- EV / EBITDA
- 17.6×
- Price / sales
- 3.40×
- Price / book
- 7.30×
- Market cap
- $10.4Bprice × diluted shares
- Enterprise value
- $10.8B
Growth
- Revenue, 12 months
- $3.1B
- Sales growth, 12 months
- +29.4%vs the 12 months before
- Sales growth, 3 yrs
- +27.5%/yrfrom FY2022
- Diluted EPS, 12 months
- $5.33
- EPS growth, last FY
- −39.8%
- Net income, 12 months
- $375M
- Net income growth
- +59%12 months vs before
Profitability
- Gross margin
- 71.1%
- Operating margin
- 16.9%
- Net margin
- 12.3%
- FCF margin
- 9.6%
- Return on equity
- 26%
- Return on invested capital
- 21%
Balance sheet
- Cash & short-term inv.
- $535M
- Total debt
- $948M
- Net cash
- −$414M
- Debt / equity
- 0.67×
- Interest coverage
- 8.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $294M
- FCF growth, 12 months
- −27%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $330M3.2% of market cap
- Share count, 1 year
- −1.8%diluted shares vs a year ago
- Stock-based comp
- $78M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Insulet’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $130.56 · MV $138.35 · FCF value $84.72
Assumes 15.0% growth for 5 years (revenue grew 27.5% a year FY22–FY25; capped at 15%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $4.23 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 5, 2026.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 62 · 5 days +0.4%
The business
FCF $0.2B · Sales +24%
- Free cash flow, 12 months$0.2B
- Free-cash-flow yield2.3%
- Free-cash-flow margin8%
- Gross margin71%
- Operating margin16%
- Return on invested capital20%
- Return on equity26%
- Sales growth (latest quarter vs year-ago quarter)+24%
- Net debt / EBITDA0.8×
Next report
Nov 4
- DateWed Nov 4, before the open
- Consensus EPS$1.59
- Year-ago EPS$1.24
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
PODD is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.